KIR3DL1 and neoplasm: Therefore, we hypothesize that patients with the KIR-ligands present genotype may have more ‘licensed’ (namely more potent) NK cells that, in this setting, would not be inhibited due to the low level of HLA on their tumors and thus be associated with a greater anti-tumor effect.